
To evaluate the efficacy and zzso safety of zzso zzso solution zzso zzso once daily for the treatment of zzso inflammation and pain following cataract extraction with zzso chamber zzso lens zzso 

A total of 455 subjects zzso study zzso 230 zzso 225 zzso were enrolled in two zzso zzso zzso clinical trials at 64 zzso clinics in the United zzso zzso were zzso to receive either zzso zzso or zzso zzso once zzso zzso began 1 day before cataract surgery zzso zzso continued on day of surgery zzso zzso and for 14 days following zzso zzso were completed on Days 1, 3, 8, 15 and zzso The primary efficacy zzso was cleared summed zzso inflammation score zzso by Day zzso The secondary efficacy zzso was the number of subjects who were pain-free at Day zzso 

The zzso zzso group was significantly higher compared to the zzso group in the primary zzso of the proportion of subjects who had cleared zzso inflammation by Day 15 zzso zzso zzso The mean zzso for the zzso zzso group was lower than the zzso group at Days 3, 8, 15, and 22 zzso zzso zzso More zzso zzso subjects were pain free at Days 1, 3, 8, and 15 zzso zzso zzso Fewer subjects in the zzso zzso group withdrew from the clinical trials due to lack of efficacy at Day 15 zzso zzso zzso Fewer adverse events were reported in the zzso zzso group than the zzso zzso zzso included advanced age, female zzso and surgical zzso among cataract zzso making zzso comparisons zzso 

zzso zzso solution zzso zzso once daily is clinically safe and effective for the treatment of zzso inflammation and the reduction of zzso pain associated with cataract zzso 

